Cited by 1,635Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesFerroptosis and cancer prognosis

The DOI matches its Crossref record; 70 of the 76 references it cites were found in a registry or an index.

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Open access

Gibney, Geoffrey T, Weiner, Louis M, Atkins, Michael B·2016·The Lancet Oncology

DOI 10.1016/s1470-2045(16)30406-5PMC PMC5702534

Open this paper in CoChat — free account

Abstract

The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-related adverse events increases with combination regimens. The development of predictive biomarkers is needed to optimise patient benefit, minimise risk of toxicities, and guide combination approaches. The greatest focus has been on tumour-cell PD-L1 expression. Although PD-L1 positivity enriches for populations with clinical benefit, PD-L1 testing alone is insufficient for patient selection in most malignancies. In this Review, we discuss the status of PD-L1 testing and explore emerging data on new biomarker strategies with tumour-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochemistry. Future development of an effective predictive biomarker for checkpoint inhibitor-based immunotherapy will integrate multiple approaches for optimal characterisation of the immune tumour microenvironment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(16)30406-5

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Show all 76 references

Sorted by citations

Items 601–700 of 1,002

Pan-cancer analysis of tumor metabolic landscape associated with genomic alterations
Choi, H., & Na, K. J. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0895-9 · Cited by 26
Can CpG methylation serve as surrogate markers for immune infiltration in cancer?
Bacolod, M. D., Barany, F., & Fisher, P. B. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.007 · Cited by 25
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
Cuyàs, E., Verdura, S., Martín-Castillo, B., Alarcón, T., Lupu, R., Bosch‐Barrera, J., & Menéndez, J. A. (2020) · Cancers · doi:10.3390/cancers12071757 · Cited by 26
Neutrophil depletion enhances the therapeutic effect of PD-1 antibody on glioma
Wang, P., Zhang, Y., Su, J., Yao, K., Li, S., Huang, G., & Yan, C. (2020) · Aging · doi:10.18632/aging.103428 · Cited by 25
Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor
Ji, S., Li, J., Chang, L., Zhao, C., Jia, R., Tan, Z.-L., Liu, R., Zhang, Y., Li, Y., Yin, G., et al. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02562-4 · Cited by 25
Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
Keukeleire, S. D., Vermassen, T., Hilgert, E., Creytens, D., Ferdinande, L., & Rottey, S. (2021) · Cancers · doi:10.3390/cancers13071714 · Cited by 25
Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy
Li, R., He, Y., Zhang, H., Wang, J., Liu, X., Liu, H., Wu, H., & Liang, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690056 · Cited by 24
The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals
Wang, R., Lin, N., Mao, B., & Wu, Q. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03716-1 · Cited by 25
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
Kang, Y., Morita, S., Satoh, T., Ryu, M., Chao, Y., Kato, K., Chung, H. C., Chen, J., Muro, K., Kang, W. K., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01230-4 · Cited by 25
Association of the Geriatric Nutritional Risk Index With the Survival of Patients With Non–Small Cell Lung Cancer After Nivolumab Therapy
Karayama, M., Inoue, Y., Yoshimura, K., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y., Inui, N., et al. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000396 · Cited by 25
Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer
Lou, S., Wang, Y., Zhang, J., Yin, X., Zhang, Y., Wang, Y., & Xue, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.806324 · Cited by 25
A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer
Zuo, B., Yang, X., Yang, X., Bian, J., Long, J., Wang, D., Ning, C., Wang, Y., Xun, Z., Wang, Y., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03121-0 · Cited by 25
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy
Caliman, E., Fancelli, S., Ottanelli, C., Mazzoni, F., Paglialunga, L., Lavacchi, D., Michelet, M. R. G., Giommoni, E., Napolitano, B., Scolari, F., et al. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100603 · Cited by 24
A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer
Ding, K., He, Y., Wei, J., Fu, S., Wang, J., Chen, Z., Zhang, H., Qu, Y., Liang, K., Gong, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943090 · Cited by 23
PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
Zhong, Y.-M., Yin, K., Chen, Y., Xie, Z., Lv, Z.-Y., Yang, J., Yang, X., Zhou, Q., Wang, B.-C., Zhong, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.951817 · Cited by 25
Insights into prognosis and immune infiltration of cuproptosis-related genes in breast cancer
Huang, T., Liu, Y., Li, J., Shi, B., Shan, Z., Shi, Z., & Yang, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1054305 · Cited by 26
The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms
Liu, M., Li, N., Tang, H., Chen, L., Liu, X., Wang, Y., Lin, Y., Luo, Y., Wei, S., Wen, W., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad093 · Cited by 25
Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma
Zoroquiaín, P., Espósito, E., Logan, P. T., Aldrees, S. S., Dias, A. B. T., Mansure, J. J., Santapau, D., García-Álvarez, C., Saornil, M. A., Neto, R. B., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0043-5 · Cited by 25
PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma
Saglam, O., Zhou, J., Wang, X., & Conejo-Garcia, J. R. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000623 · Cited by 25
Precision Medicine in Soft Tissue Sarcoma Treatment
Nakano, K., & Takahashi, S. (2020) · Cancers · doi:10.3390/cancers12010221 · Cited by 25
Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma
Stein, M. K., Williard, F. W., Xiu, J., Tsao, M. W., Martin, M. G., Deschner, B. W., Dickson, P. V., Glazer, E. S., Yakoub, D., Shibata, D., et al. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.25899 · Cited by 25
The Biology of Myxofibrosarcoma: State of the Art and Future Perspectives
Sambri, A., PAOLIS, M. D., Spinnato, P., Donati, D. M., & Bianchi, G. (2020) · Oncology Research and Treatment · doi:10.1159/000507334 · Cited by 24
Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer
Zhang, Y. X., Wang, F., Sun, H., Huang, Y., Gao, J., & Huang, H. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03633-3 · Cited by 25
Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy
Singh, S. D., Singh, N., Baranwal, M., Sharma, S., Devi, S., & Kumar, S. (2023) · 3 Biotech · doi:10.1007/s13205-023-03826-2 · Cited by 24
Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors
Conroy, M. R., O’Sullivan, H., Collins, D. C., Bambury, R. M., Power, D. G., Grossman, S. A., & O’Reilly, S. (2024) · BJC Reports · doi:10.1038/s44276-024-00058-6 · Cited by 24
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Dugo, M., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Seitz, R. S., Nielsen, T. J., Thill, M., Antón, A., Russo, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0149 · Cited by 27
Bladder cancer immune-related markers: diagnosis, surveillance, and prognosis
Yang, T., Luo, W., Yu, J., Zhang, H., Hu, M., & Tian, J. Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1481296 · Cited by 24
Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues
Wu, X., Zhu, L., & Ma, P. C. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199767 · Cited by 23
WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype
Zimmer, K., Puccini, A., Xiu, J., Baca, Y., Spizzo, G., Lenz, H., Battaglin, F., Goldberg, R. M., Grothey, A. F., Shields, A. F., et al. (2020) · Cancers · doi:10.3390/cancers12051319 · Cited by 24
Characterization of Neoantigen Load Subgroups in Gynecologic and Breast Cancers
Zhu, Y., Meng, X., Ruan, X., Lu, X., Yan, F., & Wang, F. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00702 · Cited by 26
Assessment of long non-coding RNA expression reveals novel mediators of the lung tumour immune response
Sage, A. P., Ng, K. W., Marshall, E. A., Stewart, G. L., Minatel, B. C., Enfield, K. S. S., Martin, S. D., Brown, C. J., Abraham, N., & Lam, W. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-73787-6 · Cited by 22
Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model
Carlson, P. M., Mohan, M., Rodriguez, M., Subbotin, V. M., Sun, C. X., Patel, R. B., Birstler, J., Hank, J. A., Rakhmilevich, A. L., Morris, Z. S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002107 · Cited by 24
Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
Cao, L., Prithviraj, P., Shrestha, R., Sharma, R., Anaka, M., Bridle, K. R., Kannourakis, G., Crawford, D. H., & Jayachandran, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102191 · Cited by 24
Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
Lim, Y. W., Coles, G. L., Sandhu, S. K., Johnson, D. S., Adler, A. S., & Stone, E. L. (2021) · BMC Biology · doi:10.1186/s12915-021-01034-z · Cited by 26
Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
Dart, S., Cook, A., Millward, M., McDonnell, A. M., Chin, W. L., Hakeem, M. U., Meniawy, T. M., & Bowyer, S. E. (2021) · Scientific Reports · doi:10.1038/s41598-021-93479-z · Cited by 24
Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
Hellwig, K., Ellmann, S., Eckstein, M., Wiesmueller, M., Rutzner, S., Semrau, S., Frey, B., Gaipl, U. S., Gostian, A., Hartmann, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.734872 · Cited by 24
A Cancer Associated Fibroblasts-Related Six-Gene Panel for Anti-PD-1 Therapy in Melanoma Driven by Weighted Correlation Network Analysis and Supervised Machine Learning
Tian, L., Long, F., Hao, Y., Li, B., Li, Y., Tang, Y., Li, J., Zhao, Q., Chen, J., & Liu, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.880326 · Cited by 25
Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: A systematic review and meta-analysis
Wang, N., Qin, Y., Du, F., Wang, X., & Song, C. (2022) · Gene · doi:10.1016/j.gene.2022.146638 · Cited by 24
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab
Watson, G. A., Sanz‐García, E., Zhang, W., Liu, Z. A., Yang, S. C., Wang, B., Liu, S., Kubli, S. P., Berman, H. K., Pfister, T. D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004378 · Cited by 24
Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study
Ueki, H., Hara, T., Okamura, Y., Bando, Y., Terakawa, T., Furukawa, J., Harada, K., Nakano, Y., & Fujisawa, M. (2022) · Korean journal of urology · doi:10.4111/icu.20220028 · Cited by 25
Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives
Pallozzi, M., Tommaso, N. D., Maccauro, V., Santopaolo, F., Gasbarrini, A., Ponziani, F. R., & Pompili, M. (2022) · Cancers · doi:10.3390/cancers14194631 · Cited by 27
PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers
Dai, J., Cui, Y., Xiao, L., Xu, J., Li, J., Chen, Y., Zhang, E., & Guo, R. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1066347 · Cited by 26
Downregulation of phosphoserine phosphatase potentiates tumor immune environments to enhance immune checkpoint blockade therapy
Peng, Z.-P., Liu, X.-C., Ruan, Y.-H., Jiang, D., Huang, A.-Q., Ning, W.-R., Jiang, Z.-Z., Zheng, L., & Wu, Y. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005986 · Cited by 24
SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy
Zheng, X., Lin, J., Xiong, J., Guan, Y., Lan, B., Li, Y., Gao, X., Fei, Z., Chen, L., Chen, L., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10920-4 · Cited by 22
Association of the CD4+/CD8+ ratio with response to PD-1 inhibitor-based combination therapy and dermatological toxicities in patients with advanced gastric and esophageal cancer
Xu, S., Zhu, Q., Wu, L., Wang, Y., Wang, J., Zhu, L., Zheng, S., Hang, J., & Hang, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110642 · Cited by 22
Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer
Decazes, P., Ammari, S., Belkouchi, Y., Mottay, L., Lawrance, L., de Prévia, A., Talbot, H., Farhane, S., Cournède, P.-H., Marabelle, A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007315 · Cited by 24
Regulation of T cell antitumor immune response by tumor induced metabolic stress
Chalmin, F., Bruchard, M., Végran, F., & Ghiringhelli, F. (2019) · Cell Stress · doi:10.15698/cst2019.01.171 · Cited by 23
Combined Assessment of the Tumor–Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer
Ravensbergen, C. J., Polack, M., Roelands, J. P., Crobach, S., Putter, H., Gelderblom, H. A. J., Tollenaar, R. A. �. �., & Mesker, W. E. (2021) · Cells · doi:10.3390/cells10112935 · Cited by 25
Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay
Quy, P. N., Kanai, M., Fukuyama, K., Kou, T., Kondo, T., Yamamoto, Y., Matsubara, J., Hiroshima, A., Mochizuki, H., Sakuma, T., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0587 · Cited by 23
Current development of molecular classifications of gastric cancer based on omics (Review)
Ma, Y., Jiang, Z., Pan, L., Zhou, Y., Xia, R., Liu, Z., & Li, Y. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5677 · Cited by 30
Portable Point-of-Care Diagnosis Platforms and Emerging Predictive Biomarkers for Rapid Detection of Severe Dengue Viral Infection
Vairaperumal, T., Lee, P.-T., & Liu, P. (2025) · ACS Sensors · doi:10.1021/acssensors.5c00263 · Cited by 23
Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
Li, H., Chang, Y., Jin, T., & Zhang, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03769-z · Cited by 23
The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018
Dahl, O., & Brydøy, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1555375 · Cited by 24
Changes in the tumor immune microenvironment in resected recurrent soft tissue sarcomas
Zheng, B., Wang, J., Cai, W., Lao, I. W., Shi, Y., Luo, X., & Yan, W. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.43 · Cited by 23
In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea?
Castiello, L., Aricò, E., D'Agostino, G., Santodonato, L., & Belardelli, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02303 · Cited by 23
Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine
Albershardt, T. C., Parsons, A. J., Reeves, R. S., Flynn, P., Campbell, D. J., ter Meulen, J., & Berglund, P. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.02.034 · Cited by 23
Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients
Gérard, A. O., Doyen, J., Crémoni, M., Bailly, L., Zorzi, K., Ruetsch-Chelli, C., Brglez, V., Picard‐Gauci, A., Troin, L., Esnault, V. L. M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002512 · Cited by 23
MCAM/MUC18/CD146 as a Multifaceted Warning Marker of Melanoma Progression in Liquid Biopsy
Rapanotti, M. C., Cugini, E., Nuccetelli, M., Terrinoni, A., Raimondo, C. D., Lombardo, P., Costanza, G., Cosio, T., Rossi, P., Orlandi, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212416 · Cited by 23
C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma
Klümper, N., Schmucker, P., Hahn, O., Hoeh, B., Mattigk, A., Banek, S., Ellinger, J., Heinzelbecker, J., Sikic, D., Eckstein, M., et al. (2021) · OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) · doi:10.18725/oparu-44459 · Cited by 23
Effect of Systemic or Intraperitoneal Administration of Anti-PD-1 Antibody for Peritoneal Metastases from Gastric Cancer
KUMAGAI, Y., Futoh, Y., Miyato, H., Ohzawa, H., Yamaguchi, H., Saito, S., Kurashina, K., Hosoya, Y., Lefor, A. K., Sata, N., et al. (2022) · In Vivo · doi:10.21873/invivo.12811 · Cited by 24
Identification of an autophagy-related gene signature for predicting prognosis and immune activity in pancreatic adenocarcinoma
Deng, J., Zhang, Q., Lv, L., Ma, P., Zhang, Y., Zhao, N., & Zhang, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-11050-w · Cited by 24
The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
Luo, X., Zhou, Z., Zeng, X., & Liu, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935581 · Cited by 22
RASGRP2 is a potential immune-related biomarker and regulates mitochondrial-dependent apoptosis in lung adenocarcinoma
Liu, Y., Ouyang, Y., Feng, Z., Jiang, Z., Ma, J., Zhou, X., Cai, C., Han, Y., Zeng, S., Liu, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1100231 · Cited by 23
Combining WGCNA and machine learning to construct basement membrane-related gene index helps to predict the prognosis and tumor microenvironment of HCC patients and verifies the carcinogenesis of key gene CTSA
Sun, W., Wang, J., Wang, Z., Xu, M., Lin, Q., Sun, P., & Yuan, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1185916 · Cited by 24
Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancer
Guler, G. D., Ning, Y., Çoruh, C., Mognol, G. P., Phillips, T. C., Nabiyouni, M., Hazen, K., Scott, A., Volkmuth, W., & Levy, S. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008028 · Cited by 23
Mismatch repair–deficient colorectal cancer: a model of immunogenic and immune cell–rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells
Flahec, G. L., Badic, B., Guibourg, B., Doucet, L., Bail, J. P., Marcorelles, P., Schick, U., & Uguen, A. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.09.019 · Cited by 22
Eukaryotic elongation factor-2 kinase expression is an independent prognostic factor in colorectal cancer
Ng, T. H., Sham, K. W. Y., Xie, C., Ng, S. S. M., To, K. F., TONG, J. H. M., Liu, W. Y.-Z., Zhang, L., Chan, M. T. V., Wu, W. K. K., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5873-0 · Cited by 23
Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report
Fang, C., Zhang, C., Zhao, W., Hu, W., Wu, J., & Ji, M. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0592-6 · Cited by 23
Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma
Zuo, S., Sho, M., Sawai, T., Kanehiro, H., Maeda, K., Yoshida, M., Tsukada, R., Nomura, M., & Okuyama, H. (2020) · Pediatric Surgery International · doi:10.1007/s00383-019-04616-9 · Cited by 23
PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma
Sughayer, M. A., Dabbagh, T. Z., & Battah, A. (2020) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000834 · Cited by 23
In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with 89Zr-labeled avelumab.
Li, M., Ehlerding, E. B., Jiang, D., Barnhart, T. E., Chen, W., Cao, T., Engle, J. W., & Cai, W. (2020) · PubMed Central · Cited by 23
Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non‐small cell lung cancer
Choi, M. G., Kim, Y. J., Lee, J. C., Rho, J. K., & Choi, C. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13677 · Cited by 25
Informatics for cancer immunotherapy
Hammerbacher, J., & Snyder, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx682 · Cited by 23
Identification of Hypoxia‐ALCAMhigh Macrophage‐ Exhausted T Cell Axis in Tumor Microenvironment Remodeling for Immunotherapy Resistance
Xun, Z., Zhou, H., Shen, M., Liu, Y., Sun, C., Du, Y., Jiang, Z., Yang, L., Zhang, Q. H., Lin, C., et al. (2024) · Advanced Science · doi:10.1002/advs.202309885 · Cited by 27
Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status
Katsura, H., Suga, Y., Araya, T., Kita, T., Yoneda, T., Tanaka, N., Kawabata, A., Sotoki, I., & Mase, H. (2019) · Journal of Cancer · doi:10.7150/jca.31217 · Cited by 22
Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry
Music, M., Iafolla, M. A. J., Soosaipillai, A. R., Batruch, I., Prassas, I., Pintilie, M., Hansen, A. R., Bedard, P. L., Lheureux, S., Spreafico, A., et al. (2020) · F1000Research · doi:10.12688/f1000research.22715.1 · Cited by 22
Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer
Hakozaki, T., Hosomi, Y., Kitadai, R., Kitagawa, S., & Okuma, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03271-1 · Cited by 22
Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets
Gupta, I., Rizeq, B. R., Vranić, S., Moustafa, A. A., & Farsi, H. F. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186750 · Cited by 23
New biomarkers for checkpoint inhibitor therapy
Burdett, N. L., & Desai, J. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000597 · Cited by 23
A bioengineered organotypic prostate model for the study of tumor microenvironment-induced immune cell activation
Kerr, S. C., Morgan, M. M., Gillette, A. A., Livingston, M. K., Lugo-Cintrón, K. M., Favreau, P. F., Florek, L., Johnson, B. P., Lang, J. M., Skala, M. C., et al. (2020) · Integrative Biology · doi:10.1093/intbio/zyaa020 · Cited by 21
Biomarkers for predicting the outcome of various cancer immunotherapies
Jafarzadeh, L., Khakpoor-Koosheh, M., Mirzaei, H., & Mirzaei, H. R. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103161 · Cited by 21
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis
Iafolla, M. A. J., Yang, C., Chandran, V., Pintilie, M., Li, Q., Bedard, P. L., Hansen, A. R., Lheureux, S., Spreafico, A., Razak, A. A., et al. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa115 · Cited by 21
Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma
Chen, X., Wang, Z., Wang, G., Zhang, C., Jin, S., Jiang, G., & Bai, D. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01126-1 · Cited by 22
Enhancing Checkpoint Inhibitor Therapy in Solid Tissue Cancers: The Role of Diet, the Microbiome & Microbiome-Derived Metabolites
Malczewski, A. B., Ketheesan, N., Coward, J. I. G., & Navarro, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624434 · Cited by 22
Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?
Goff, P. H., Bhakuni, R., Pulliam, T. H., Lee, J. H., Hall, E. T., & Nghiem, P. (2021) · Cancers · doi:10.3390/cancers13143415 · Cited by 23
Radionuclide-based theranostics — a promising strategy for lung cancer
Zhu, T., Hsu, J. C., Guo, J., Chen, W., Cai, W., & Wang, K. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06174-8 · Cited by 22
Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
Zila, N., Eichhoff, O. M., Steiner, I., Mohr, T. T., Bileck, A., Cheng, P. F., Leitner, A., Gillet, L. C. J., Sajic, T., Goetze, S., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0562 · Cited by 23
Construction of Anti-hPD-L1 HCAb Nb6 and in Situ 124I Labeling for Noninvasive Detection of PD-L1 Expression in Human Bone Sarcoma
Huang, H.-F., Zhu, H., Li, G., Xie, Q., Yang, X., Xu, X., Tian, X., Wan, Y., & Yang, Z. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00539 · Cited by 22
Noninvasive PET tracking of post-transplant gut microbiota in living mice
Wang, Y., Zhang, C., Lai, J., Zhao, Y., Lu, D., Bao, R., Feng, X., Zhang, T., & Liu, Z. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04639-3 · Cited by 22
Recent Findings in the Posttranslational Modifications of PD-L1
Li, S., Zhou, J., Wang, Y., Nie, R., Chen, J., & Xie, D. (2020) · Journal of Oncology · doi:10.1155/2020/5497015 · Cited by 22
Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade
Natoli, M., Bonito, N. A., Robinson, J. D., Ghaem‐Maghami, S., & Mao, Y. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02544-5 · Cited by 22
Expression of human leukocyte antigen class I and β2‐microglobulin in colorectal cancer and its prognostic impact
Na, H. Y., Park, Y., Nam, S. K., Lee, K. S., Oh, H., Kim, D., Kang, S., Kim, W. H., & Lee, H. S. (2020) · Cancer Science · doi:10.1111/cas.14723 · Cited by 21
Identification of an Autophagy-Related Pair Signature for Predicting Prognoses and Immune Activity in Pancreatic Adenocarcinoma
Zhang, Q., Lv, L., Ma, P., Zhang, Y., Deng, J., & Zhang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.743938 · Cited by 22
Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities
López‐Janeiro, Á., Wong, E. M., Jiménez‐Sánchez, D., Ortíz-de-Solórzano, C., Lozano, M. D., Teijeira, Á., Schalper, K. A., Melero, I., & de Andrea, C. E. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008589 · Cited by 23
Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
Qiu, M., Bai, Y., Wang, J., Gu, K., Yang, M., He, Y., Cheng, Y., Jin, Y., Liu, B., Wang, F., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02063-0 · Cited by 21
Pyroptosis‐Inducing Platinum(IV) Prodrugs via GSDME Pathway for Chemoimmunotherapy and Metastasis Inhibition in Triple‐Negative Breast Cancer
Yang, X., Xu, C., Zeng, Y., Wang, C., Gao, Y., Ding, J., Chen, S., Pan, Y., Zhang, X., Mao, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202505567 · Cited by 23
Predictive Biomarkers for PD-1 and PD-L1 Immune Checkpoint Blockade Therapy
Song, Y., Li, Z., Xue, W., & Zhang, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0173 · Cited by 21
Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments
Sivanand, A., Surmanowicz, P., Alhusayen, R. O., Hull, P. R., Litvinov, I. V., Zhou, Y., & Gniadecki, R. (2019) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475419867610 · Cited by 21
Multimodal detection of PD-L1: reasonable biomarkers for immune checkpoint inhibitor.
Yang, Q., Xu, Z., Zheng, L., Zhang, L., You, Q., & Sun, J. (2018) · Europe PMC (PubMed Central) · Cited by 21
Pan-cancer immunogenomic analyses reveal sex disparity in the efficacy of cancer immunotherapy
Wang, P., Song, H., Zhang, Q., & Yan, C. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.12.008 · Cited by 21

Authors: Gibney, G. T., Weiner, L. M., & Atkins, M. B.
Affiliations: Georgetown University Medical Center (US)
Corresponding author: Gibney, Geoffrey T
ORCID: Gibney, Geoffrey T
Weiner, Louis M
Atkins, Michael B
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2016-12
Volume: 17
Issue: 12
Pages: e542-e551
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(16)30406-5
PMC: PMC5702534
OpenAlex: W2559382297
Cited by: 1,635
References: 76
Citations by year: 2026: 62 · 2025: 111 · 2024: 161 · 2023: 222 · 2022: 238 · 2021: 229 · 2020: 248 · 2019: 171 · 2018: 109 · 2017: 83
FWCI: 11.76
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA050633, P30CA051008)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords: predictive biomarkers, immune checkpoint inhibitors, PD-1, PD-L1 expression, tumor-infiltrating lymphocytes, tumor mutational burden, immune-related gene signature, multiplex immunohistochemistry, immune-related adverse events, patient selection, melanoma
MeSH terms: Humans, Immunohistochemistry, Immunotherapy, Neoplasms, Biomarkers, Lymphocytes, Tumor-Infiltrating, Tumor Microenvironment, Cell Cycle Checkpoints, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks